← All companies

RNA

Atrium Therapeutics, Inc.

RNA Nasdaq Pharmaceutical Preparations EDGAR ↗

$11.33

-0.13 -1.13%

Key statistics

from XBRL data in SEC filings

Market cap

$194M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$268M

Total assets

$292M

Gross margin

—

52-week range

$11.13 – $16.77

Recent SEC filings

38 most recent

Annual, quarterly & current reports

8-K Other events Jul 14, 2026 10-Q Quarter ended 2026-03-31 May 14, 2026 8-K Results of operations (earnings release) May 14, 2026 8-K Entered a material agreement; Change in control; Director or officer change Feb 27, 2026 8-K Regulation FD disclosure Feb 26, 2026

Other filings

SCHEDULE 13G/A Jul 27, 2026 SCHEDULE 13G May 15, 2026 SCHEDULE 13G Apr 27, 2026 4 Apr 22, 2026 4 Apr 22, 2026 4 Apr 22, 2026 4 Apr 22, 2026 4 Apr 22, 2026 4 Apr 22, 2026 S-8 Apr 17, 2026 SCHEDULE 13G Apr 8, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 S-8 Feb 26, 2026 SEC STAFF ACTION Feb 26, 2026 CERT Feb 26, 2026 10-12B/A Feb 17, 2026 10-12B/A Jan 30, 2026 10-12B Dec 10, 2025